-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, P0m8pwj/7LmWhgDC4QF8YhDPmIt4bYthY81e6s71fSiaAR2zZReQAtzPDLNP1S0u iyZpZDEhvYDNf1flz/fRXw== 0000893838-99-000112.txt : 19990511 0000893838-99-000112.hdr.sgml : 19990511 ACCESSION NUMBER: 0000893838-99-000112 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19990510 FILED AS OF DATE: 19990510 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: SEC FILE NUMBER: 000-26372 FILM NUMBER: 99615303 BUSINESS ADDRESS: STREET 1: 1065 E HILLSDALE BLVD STREET 2: SUITE 418 CITY: FORSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 4153826770 MAIL ADDRESS: STREET 1: 1065 E HILLSDALE BLVD STREET 2: SUITE 418 CITY: FORSTER CITY STATE: CA ZIP: 94404 COMPANY DATA: COMPANY CONFORMED NAME: FOUR PARTNERS CENTRAL INDEX KEY: 0000942714 STANDARD INDUSTRIAL CLASSIFICATION: [] OWNER STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 BUSINESS ADDRESS: STREET 1: C/O BARRY L BLOOM STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 212-545-2930 4 1 FORM 4 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 / / Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person*: Four Partners ------------------------------ (LAST) (FIRST) (MIDDLE) c/o Thomas J. Tisch 667 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value ("Common Stock") 2. Transaction Date: (Month/Day/Year) 4/14/99 3. Transaction Code: (Instr. 8) Code P 2 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5,000 A 3.375 4/14/99 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 5,000 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 3 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) 4 Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: This Form 4 is being filed jointly by the following individuals and entities: 1. Thomas J. Tisch; 2. Daniel R. Tisch; 3. James S. Tisch; 4. Andrew H. Tisch (Thomas J. Tisch, Daniel R. Tisch, James S. Tisch and Andrew H. Tisch are referred to collectively as the "Messrs. Tisch"); 5. Four-Fourteen Partners, LLC, a Delaware limited liability company ("4-14P"); 6. Four Partners, a New York general partnership ("FP") 7. The Thomas J. Tisch 1999 Annuity Trust I ("Thomas Tisch GRAT I"); 5 8. The Daniel R. Tisch 1999 Annuity Trust I ("Daniel Tisch GRAT I"); 9. The James S. Tisch 1999 Annuity Trust I ("James Tisch GRAT I"); and 10. The Andrew H. Tisch 1999 Annuity Trust I ("Andrew Tisch GRAT I"; and collectively with Thomas Tisch GRAT I, Daniel Tisch GRAT I and James Tisch GRAT I, the "GRATs I"). FP is the designated filer. The sole partners of FP are Andrew H. Tisch 1991 Trust, for which Andrew H. Tisch is the managing trustee, Daniel R. Tisch 1991 Trust, for which Daniel R. Tisch is the managing trustee, James S. Tisch 1991 Trust, for which James S. Tisch is the managing trustee, and Thomas J. Tisch 1991 Trust, for which Thomas J. Tisch is the managing trustee. Thomas J. Tisch has been appointed the Manager of FP. Andrew H. Tisch, Daniel R. Tisch, James S. Tisch and Thomas J. Tisch are referred to herein as the "Messrs. Tisch." The members of 4-14P are trusts for the benefit of the offspring of the Messrs. Tisch, partnerships the partners of which are such trusts and partnerships the partners of which are such partnerships. The Messrs. Tisch serve as the trustees of such trusts. Thomas J. Tisch has been appointed the Manager of 4-14P. Each of the GRATs I is a grantor retained annuity trust in which the grantor holds an annuity interest and in which the remainder interest was created in favor of a trust or trusts for the grantor's offspring. Thomas J. Tisch is the grantor and Andrew H. Tisch is the trustee of Thomas Tisch GRAT I. Daniel R. Tisch is the grantor and James S. Tisch is the trustee of Daniel Tisch GRAT I. James S. Tisch is the grantor and Thomas J. Tisch is the trustee of James Tisch GRAT I. Andrew H. Tisch is the grantor and Daniel R. Tisch is the trustee of Andrew Tisch GRAT I. Each of the Messrs. Tisch is herein reporting beneficial ownership of the shares of Common Stock owned by the GRAT I for which he is the grantor. The filing of this statement is not an admission by any Reporting Person that such Reporting Person and any other person or persons constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that any Reporting Person is the beneficial owner of any securities owned by any other person. [Signatures follow all attachments] 6 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Four-Fourteen Partners LLC ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Thomas J. Tisch 667 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director 7 _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: 8 (Instr. 3 and 4) 47,700 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) 9 Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 11. Nature of Indirect Beneficial Ownership: 10 (Instr. 4) Explanation of Responses: See Form 4 of FP [Signatures follow all attachments] 11 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Thomas J. Tisch 1999 Annuity Trust I ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Barry Bloom 655 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director 12 _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: 13 (Instr. 3 and 4) 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: 14 (Instr. 8) Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 15 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: See Form 4 of FP [Signatures follow all attachments] 16 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Daniel R. Tisch 1999 Annuity Trust I ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Barry Bloom 655 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director 17 _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: 18 (Instr. 3 and 4) 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) 19 Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 20 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 21 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: James S. Tisch 1999 Annuity Trust I ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Barry Bloom 655 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director 22 _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: 23 (Instr. 3 and 4) 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: 24 (Instr. 8) Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 25 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 26 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Andrew H. Tisch 1999 Annuity Trust I ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Thomas J. Tisch 655 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director _____ Officer (give title below) 27 __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 28 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) D 7. Nature of Indirect Beneficial Ownership: (Instr. 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) Code 29 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 11. Nature of Indirect Beneficial Ownership: (Instr. 4) 30 Explanation of Responses: [Signatures follow all attachments] 31 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Thomas J. Tisch ------------------------------------------ (LAST) (FIRST) (MIDDLE) 667 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director 32 _____ Officer (give title below) __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 33 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) I 7. Nature of Indirect Beneficial Ownership: (Instr. 4) (See explanation to Form 4 of FP) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: 34 (Instr. 8) Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 35 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 36 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Daniel R. Tisch ------------------------------------------ (LAST) (FIRST) (MIDDLE) c/o Mentor Partners, L.P. 500 Park Avenue ------------------------------------------- (STREET) New York, New York 10022 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director _____ Officer (give title below) 37 __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 38 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) I 7. Nature of Indirect Beneficial Ownership: (Instr. 4) (See explanation to Form 4 of FP) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) 39 Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 40 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 41 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: James S. Tisch ------------------------------------------ (LAST) (FIRST) (MIDDLE) 667 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director _____ Officer (give title below) 42 __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 43 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) I 7. Nature of Indirect Beneficial Ownership: (Instr. 4) (See explanation to Form 4 of FP) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: (Instr. 8) 44 Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 45 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 46 Attachment To Form 4 of Four Partners in Respect of Cellegy Pharmaceuticals, Inc. (CLGY) Statement for: 4/99 Joint Filer Information 1. Name and Address of Reporting Person*: Andrew H. Tisch ------------------------------------------ (LAST) (FIRST) (MIDDLE) 667 Madison Avenue ------------------------------------------- (STREET) New York, New York 10021 ------------------------------------------ (CITY) (STATE) (ZIP) 2. Issuer Name and Ticker or Trading Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) 3. IRS Identification Number of Reporting Person, if an entity (Voluntary): 4. Statement for Month/Year: 4/99 5. If Amendment, Date of Original: (Month/Year) 6. Relationship of Reporting Person(s) to Issuer: (Check all applicable) _____ Director _____ Officer (give title below) 47 __X__ 10% Owner _____ Other (specify below) 7. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person _X___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security: (Instr. 3) Common Stock, no par value 2. Transaction Date: (Month/Day/Year) 3. Transaction Code: (Instr. 8) Code 4. Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) Amount (A) or (D) Price 5. Amount of Securities Beneficially Owned at End of Month: (Instr. 3 and 4) 48 578,100 6. Ownership Form: Direct (D) or Indirect (I): (Instr. 4) I 7. Nature of Indirect Beneficial Ownership: (Instr. 4) (See explanation to Form 4 of FP) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security: (Instr. 3) 2. Conversion or Exercise Price of Derivative Security: 3. Transaction Date: (Month/Day/Year) 4. Transaction Code: 49 (Instr. 8) Code 5. Number of Derivative Securities Acquired (A) or Disposed of (D): (Instr. 3, 4 and 5) (A) (D) 6. Date Exercisable and Expiration Date: (Month/Day/Year) Date Exercisable Expiration Date 7. Title and Amount of Underlying Securities: (Instr. 3 and 4) Title Amount or Number of Shares 8. Price of Derivative Security: (Instr. 5) 9. Number of Derivative Securities Beneficially Owned at End of Month: (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I): (Instr. 4) 50 11. Nature of Indirect Beneficial Ownership: (Instr. 4) Explanation of Responses: [Signatures follow all attachments] 51 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. FOUR PARTNERS By /s/ Thomas J. Tisch --------------------------------- Thomas J. Tisch, Manager FOUR-FOURTEEN PARTNERS, LLC By /s/ Thomas J. Tisch --------------------------------- Thomas J. Tisch, Manager /s/ Andrew H. Tisch ----------------------------------- Andrew H. Tisch /s/ Daniel R. Tisch ----------------------------------- Daniel R. Tisch /s/ James S. Tisch ----------------------------------- James S. Tisch /s/ Thomas J. Tisch ----------------------------------- Thomas J. Tisch THE ANDREW H. TISCH 1999 ANNUITY TRUST I By /s/ Daniel R. Tisch --------------------------------- Daniel R. Tisch, Trustee 52 THE DANIEL R. TISCH 1999 ANNUITY TRUST I By /s/ James S. Tisch --------------------------------- James S. Tisch, Trustee THE JAMES S. TISCH 1999 ANNUITY TRUST I By /s/ Thomas J. Tisch --------------------------------- Thomas J. Tisch, Trustee THE THOMAS J. TISCH 1999 ANNUITY TRUST I By /s/ Andrew H. Tisch --------------------------------- Andrew H. Tisch, Trustee Date: May 10, 1999 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of the Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. 53 -----END PRIVACY-ENHANCED MESSAGE-----